ARCHIVES

ODAC Recommends TICE BCG Approval For Recurrent Bladder Cancer Prevention

This article is from The Cancer Letter archive.

Vol. 23 No. 01 | January 10, 1997

Download PDF Visit The Full Archive

Related Articles

As Leadership Changes Continue, Fontaine, Leach Get New Posts

January 17, 2014

Ibrutinib Increases OS, PFS Versus Ofatumumab in Phase III

June 27, 2014

Center Bitter Over NCI’s Reacting To IOM report, Core grant Losses, Program Staff Cuts

June 30, 1989

Survival For ALL Increased To 94 Percent In Recent Years

December 31, 2010

FDA News: FDA Taking Comments on “First Generic” ANDA Process

November 21, 2014

In Brief: House Money Bill Reportedly Will Not Increase

September 18, 1981